Call for Comment: SITC Immune Checkpoint Inhibitor-related Adverse Events Clinical Practice Guideline This manuscript will be SITC’s second toxicity guideline, featuring comprehensive recommendations for the management of toxicities that may arise with immune checkpoint inhibitor (ICI) therapy.
Comments due on Monday, February 8.
2021 SITC Fellowships: $350,000 in funding opportunities
Advance your cancer immunotherapy research with a SITC Fellowship! Early career scientists from academia and government are encouraged to apply. Applications are due April 2, 2021.
Taught by leading experts in the field, this program, being held virtually Feb. 22–24, provides a deep understanding of the core principles of tumor immunology and cancer immunotherapy as well as developing areas in the field including biomarker technology, validation and clinical integration; clinical trial design, data analysis and considerations for combination therapies.
On Dec. 23, 2020, SITC published a statement of recommendation on SARS-CoV-2 vaccinations and cancer patients receiving immunotherapy.
Access SITC Surgery Committee’s Recent JITC Publication“Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee”
In Module 3, Immune Checkpoint Blockade, participants will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.
Review data presented at the 35th Anniversary Annual Meeting & Pre-Conference Programs in the SITC 2020 regular abstract pre-print published in the Journal for ImmunoTherapy of Cancer (JITC)! SITC welcomed over 5,200 cancer immunotherapy professionals to SITC 2020 this November, our first ever virtual annual meeting!
Comprised of several authoritative reviews of checkpoints beyond PD-1, this series, edited by Ana Carrizosa Anderson and Dario A.A. Vignali, promotes the tremendous research that is opening new pathways for treating patients with cancer.
Now Available: SITC Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma
The Society for Immunotherapy of Cancer (SITC) is committed to providing the most current COVID-19 information and resources to its members and the oncology community at large.
Join Brianna Hoffner, MSN, ANP-BC, AOCNP, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.
New Online Patient Course Available: Understanding Cancer Immunotherapy Access SITC’s dedicated resource for patients and caregivers to learn about cancer immunotherapy
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in tumor immunology and cancer immunotherapy.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
Purpose: Conversations directly relevant to patient care Audience: Practicing clinicians and staff, clinical investigators Suggested topics: demographics, clinical presentation, diagnostic testing, patient management issues/insights, patterns in ...
Purpose: Conversations directly relevant to research Audience: Laboratory and translational scientists Suggested topics: Data sharing, emerging literature, sample/tissue collection, model/reagent development, opportunities for collaboration, translational ...
I wanted to notify my fellow community members that SITC recently announced they are offering $350,000 in funding for domestic and international early career investigators in academia and government to advance their cancer immunotherapy ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org